Key Highlights

  • Published market data on November 4, 2026 showed UroGen Pharma (NASDAQ:URGN) at USD 28.16, down 18.15%, with a market cap of about USD 1.38 billion and Volume of 695,950 shares.
  • UroGen Pharma (NASDAQ:URGN) reported third quarter total Revenue of USD 89.0 million against USD 27.5 million, with ZUSDURI net product revenue of USD 68.0 million, up 35% from the second quarter.
  • JELMYTO net product revenue was USD 21.0 million against USD 25.7 million, and the company lowered its 2026 JELMYTO revenue outlook to about USD 90 million from USD 97 million to USD 101 million.
  • The net loss narrowed to USD 1.5 million, or USD 0.03 per share, from USD 33.3 million, and cash and marketable securities were USD 90.5 million.

A Strong Launch and a Weaker Legacy Product

The company announced third quarter results on November 4, 2026. ZUSDURI net product revenue was USD 68.0 million, up 35% from the second quarter, and JELMYTO net product revenue was USD 21.0 million, down from USD 25.7 million a year earlier. The two sum to the USD 89.0 million of total revenue, which compares with USD 27.5 million in the third quarter of 2025. The net loss narrowed sharply to USD 1.5 million. The company then lowered its 2026 JELMYTO net product revenue outlook to about USD 90 million from USD 97 million to USD 101 million, which probably matters to the move but is not a confirmed cause.

Pipeline, Cash and the Biggest Losers Screen

The FDA accepted the NDA for UGN-103 with a PDUFA date of June 14, 2027, the first patient was dosed in the UGN-501 Phase 1 trial, and the company entered a collaboration with IntraGel Therapeutics. Operating expenses are still expected at USD 260 million to USD 270 million for 2026, toward the upper end. Against that, cash and marketable securities of USD 90.5 million is modest, although rising product revenue now offsets a growing share of spending. A biggest losers screen ranks stocks by one-day decline within a market cap band of USD 300 million to USD 2 billion.

Risks and What to Watch

UroGen Pharma (NASDAQ:URGN) depends on a small set of urology products, and a launch can slow after an early surge. Reimbursement, physician adoption and competition will decide whether ZUSDURI sales keep climbing. The lower JELMYTO outlook suggests the older product may be cannibalized or slowing. With limited cash against high operating expenses, financing is a possibility, and Equity sales would dilute holders. Published market data shows trailing EPS of negative USD 1.99. The next dated events are the UGN-103 PDUFA date on June 14, 2027 and the fourth quarter report, and a fall of 18.2% can extend or reverse.

Where Things Stand

The 18.2% slide came on the day of a quarter with sharply higher revenue and a nearly break-even loss, so the likely trigger is the lower JELMYTO outlook and the modest cash balance, although no single cause has been confirmed. ZUSDURI is clearly ramping, with sales rising 35% in a single quarter. UroGen Pharma (NASDAQ:URGN) now has to show that growth in the new product outweighs weakness in the old one and that spending can be funded without heavy dilution. The PDUFA date in June 2027 adds a further catalyst, but approval is never assured, and any equity offering to fund operations before then could pressure the shares even if sales continue to grow at a healthy pace in the coming quarters.